A Phase III Study of Apixaban in Patients With Atrial Fibrillation (AVERROES)

Tracking Information

Start Date  ICMJESeptember 2007
Estimated Primary Completion DateAugust 2010   (final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE 
 (submitted: April 17, 2009)
The primary efficacy outcome will be the time (days) from first dose of study drug to first occurrence of unrefuted ischemic stroke, hemorrhagic stroke or systemic embolism [ Time Frame: Time to first occurrence ] [ Designated as safety issue: No ]
Original Primary Outcome Measures  ICMJE 
 (submitted: July 2, 2007)
To determine if apixaban 5 mg BID (2.5 mg BID in selected patients) is superior to ASA (81 to 324 mg QD) for preventing the composite outcome of stroke or systemic embolism in patients with atrial fibrillation and at least one additional risk factor [ Time Frame: Time to first occurrence ]
Change HistoryComplete list of historical versions of study NCT00496769 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE 
 (submitted: April 17, 2009)
The secondary efficacy outcome will be the time (days) from first dose of study drug to first occurrence of unrefuted Ischemic stroke, hemorrhagic stroke, systemic embolism, myocardial infarction, or vascular death [ Time Frame: Time to first occurrence ] [ Designated as safety issue: No ]
Original Secondary Outcome Measures  ICMJE 
 (submitted: July 2, 2007)
To determine, in the same patients, if apixaban is superior to ASA for prevention of the composite outcome of: Stroke, systemic embolism, myocardial infarction or vascular death (major vascular events) [ Time Frame: Time to first occurrence ]

Descriptive Information

Brief Title  ICMJEA Phase III Study of Apixaban in Patients With Atrial Fibrillation
Official Title  ICMJEApixaban Versus Acetylsalicylic Acid (ASA) to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment: A Randomized Double Blind Trial
Brief Summary

The purpose of this clinical research study is to learn if apixaban is more effective than Acetylsalicylic Acid (ASA) in preventing strokes associated with subjects who have atrial fibrillation. The safety of this treatment will also be studied.

Detailed Description 
Study PhasePhase III
Study Type  ICMJEInterventional
Study Design  ICMJEPrevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Safety/Efficacy Study
Condition  ICMJEAtrial Fibrillation
Intervention  ICMJE
  • Drug: Apixaban
    Tablets, Oral, 5 mg (2.5 mg in selected patients), BID, Up to 36 months/End of Study
    Other Name: BMS-562247
  • Drug: Acetylsalicylic Acid (ASA)
    Tablets, Oral, 81 - 324 mg, QD, Up to 36 months/End of Study
Study Arms / Comparison Groups
  • I: Experimental
    Intervention: Drug: Apixaban
  • II: Placebo Comparator
    Intervention: Drug: Acetylsalicylic Acid (ASA)

Recruitment Information

Estimated Enrollment  ICMJE5600
Estimated Completion DateAugust 2010
Estimated Primary Completion DateAugust 2010   (final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Permanent, paroxysmal or persistent atrial fibrillation documented by 12 lead ECG on the day of screening OR
  • If not in atrial fibrillation at screening, atrial fibrillation must be documented in the 6 months prior to enrollment by 12 lead ECF, or as an episode at least 5 minutes in duration on a rhythm strip or Holter recording. Pacemaker or ICD electrogram recordings may be used to document AF but the duration of atrial fibrillation must be at least 30 minutes if this is the only documentation of AF
  • Presence of at least one of the following risk factors for stroke:

    • Prior stroke or TIA
    • Age ≥ 75 years
    • Arterial hypertension on treatment
    • Diabetes mellitus
    • Heart failure. NYHA Class 2 or greater at time of enrollment
    • Left ventricular ejection fraction 35% or less, documented within 6 months of enrollment
    • Documented peripheral arterial disease (previous arterial revascularization, limb or foot amputation, or current intermittent claudication with ankle-arm systolic blood pressure ratio < 0.9)
    • The patient is not currently receiving vitamin K antagonist therapy for one of the following reasons:

      • Previous vitamin K antagonist therapy has been demonstrated to be unsuitable and its use has been discontinued (e.g., poor anticoagulant control, adverse events, need for other treatments that may interact with VKA, patient unable or unwilling to adhere to dose or INR monitoring instructions)
      • Vitamin K antagonist therapy has not been previously used but would be expected to be unsuitable (e.g., unlikely to comply with dosing or monitoring requirement, need for other treatments which may interact with VKA, unlikely to adhere to restrictions on alcohol, diet or non-prescription medications, risk of VKA therapy considered to outweigh the risk of stroke or systemic embolism, patient is unwilling to take VKA).
    • Men and women ≥ 50 years of age

Exclusion Criteria:

  • Women who are pregnant or breast feeding
  • Women of child bearing potential (WOCBP) who are unwilling to meet the study requirements for pregnancy testing or are unwilling or unable to use an acceptable method to avoid pregnancy.
  • Atrial fibrillation due to reversible causes (e.g., thyrotoxicosis, pericarditis)
  • Valvular disease requiring surgery
  • Planned atrial fibrillation ablation procedure to be performed within 3 months
  • Conditions other than atrial fibrillation that require chronic anticoagulation (e.g., prosthetic mechanical heart valve, venous thromboembolism
  • Patient with serious bleeding in the last 6 months or at high risk of bleeding. This includes, but is not limited to:

    • Active peptic ulcer disease
    • Platelet count < 100,000/mm3 or hemoglobin < 10g/dL
    • Recent stroke (within 10 days)
    • Documented hemorrhagic tendencies or blood dyscrasias
    • Current alcohol or drug abuse, or psychosocial reasons that make study participation impractical
    • Severe co-morbid condition with life expectancy <1 year
    • Severe renal insufficiency (creatinine clearance must be calculated in all patients: any patient with either a serum creatinine > 2.5 mg/dL [221 umol/L] or a calculated creatinine clearance < 25 ml/min is excluded)
  • ALT or AST > 2 times upper limit of normal or a total bilirubin > 1.5 times upper limit of normal (unless an alternative causative factor [e.g., Gilbert's syndrome] is identified)
  • Allergy or adverse reaction to ASA
  • See section 5.5.1 (Prohibited and/or Restricted Treatments) for therapies which are prohibited at study entry
  • Required treatment with a thienopyridine (clopidogrel or ticlopidine; see also section Acetylsalicylic acid (ASA) and Thienopyridines).
  • Prisoners or subjects who are compulsory detained (involuntarily incarcerated)
  • Use of an investigational drug or device within the past 30 days or prior randomization into an apixaban clinical study
  • Patients who are compulsorily detained for treatment of either a psychiatric or physical (e.g., infectious disease) illness
Ages50 Years and older
Accepts Healthy VolunteersNo
Contacts  ICMJE
Contact: For participation information at a USA site use a phone number below. For site information outside the USA please email:Clinical.Trials@bms.com
Contact: First line of email MUST contain NCT# & Site#. Only trial sites that are recruiting have contact information at this time.
Location Countries  ICMJEUnited States,   Argentina,   Australia,   Austria,   Belgium,   Brazil,   Canada,   Chile,   China,   Colombia,   Czech Republic,   Denmark,   Finland,   France,   Germany,   Greece,   Hong Kong,   India,   Indonesia,   Israel,   Italy,   Korea, Republic of,   Malaysia,   Mexico,   Norway,   Philippines,   Poland,   Russian Federation,   Singapore,   South Africa,   Spain,   Sweden,   Taiwan,   Turkey,   Ukraine,   United Kingdom

Administrative Information

Responsible PartyStudy Director, Bristol-Myers Squibb
Study ID Numbers  ICMJECV185-048
Study Sponsor  ICMJEBristol-Myers Squibb
Collaborators  ICMJEPfizer
Investigators  ICMJE
Study Director:Bristol-Myers SquibbBristol-Myers Squibb
Information Provided ByBristol-Myers Squibb